Talazoparib-13C, d4
Talazoparib-13C, d4 is 13C and deuterated labeled Talazoparib. Talazoparib is an orally active PARP 1/2 inhibitor with Ki values of 1.2 nM and 0.87 nM for inhibiting PARP1 and PARP2 enzymatic activities, respectively. Has anti-tumor activity.
Product Specifications
Product Name Alternative
BMN-673-13C, d4; LT-673-13C, d4
UNSPSC
12352005
Target
Isotope-Labeled Compounds
Type
Isotope-Labeled Compounds
Related Pathways
Others
Field of Research
Others
Purity
99.31
Solubility
DMSO : 25 mg/mL (ultrasonic; warming)
Smiles
O=C1NN=C2C3=C1C=C(C=C3N[13C@@H]([C@H]2C4=NC=NN4C)C5=C(C([2H])=C(C([2H])=C5[2H])F)[2H])F
Molecular Formula
C18 13CH10D4F2N6O
Molecular Weight
385.37
References & Citations
[1]Wang B, et al. Discovery and Characterization of (8S,9R) -5-Fluoro-8- (4-fluorophenyl) -9- (1-methyl-1H-1,2,4-triazol-5-yl) -2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly (ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent. J Med Chem. 2016 Jan 14;59 (1) :335-57.|[2]Shen Y, et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency.Clin Cancer Res. 2013 Sep 15;19 (18) :5003-15.|[3]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LC431419 20 µg
C16orf73 (MEIOB) (NM_001163560) Human Over-expression Lysate
Sign In for Pricing
View Details 
![APC Anti-Mouse TCRβ Antibody[H57-597]](https://cdn.genprice.uk/products/763/68dd14a6061270361e7d1ab5/imageurl/e-ab-f1123e.webp)